CD274 and cancer: Therefore, besides its emerging role as a predictive biomarker of response to immune checkpoint inhibitor-based adjuvant immunotherapy, PD-L1 expression in cancer cells also appears to be a solid candidate prognostic biomarker for early-stage LUAD patients.